Inhibikase Therapeutics (IKT) Accounts Payables (2020 - 2026)

Inhibikase Therapeutics (IKT) has 7 years of Accounts Payables data on file, last reported at $1.6 million in Q1 2026.

• On a quarterly basis, Accounts Payables fell 6.19% year-over-year to $1.6 million in Q1 2026; TTM through Mar 2026 was $1.6 million, a 6.19% decrease from a year earlier, with the FY2025 full-year figure at $1.2 million, up 22.8% from the prior year.
• Accounts Payables for Q1 2026 stood at $1.6 million, up from $1.2 million in the prior quarter.
• Over the last five years, Accounts Payables for IKT reached as high as $21.8 million in Q1 2023 and fell as low as $620528.0 in Q3 2025.
• Historically, Accounts Payables has averaged $2.9 million across 5 years, with a median of $1.3 million in 2024.
• On a YoY basis, Accounts Payables climbed as much as 2599.29% in 2023 and fell as far as 83.21% in 2023.
• Year by year, Accounts Payables stood at $1.2 million in 2022, then tumbled by 43.82% to $646767.0 in 2023, then surged by 45.81% to $943019.0 in 2024, then advanced by 22.8% to $1.2 million in 2025, then soared by 37.07% to $1.6 million in 2026.
• Per Business Quant data, the three most recent Accounts Payables figures were $1.6 million in Q1 2026, $1.2 million in Q4 2025, and $620528.0 in Q3 2025.